Income statement is strong; cash flow is moderate; balance sheet is weak.
Next earnings: 2026-10-30 (BMO), EPS Forecast: $3.74
Upgraded from Sell to Hold in the Sep 2026 quarter: 43.3 → 44.7 (+1.4). This quarter: +1.4.
Change vs previous quarter.
AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.